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Abstract
The human ovary is a complex structure that is controlled by endocrine, para-
crine, and autocrine mechanisms. The number of eggs retrieved after controlled 
ovarian stimulation in in vitro fertilization depends on the physiological follicular 
reserve pool of ovaries. Ovarian reserve is decided genetically and decreases with 
advancing age and gets affected by ovarian surgery, chemotherapy, radiotherapy, 
and autoimmune disorders. Environmental influences like chronic smoking, hyper-
glycemia, and conditions interfering ovarian vascularity also reduce the ovarian 
reserve. This chapter summarizes the methods to assess the ovarian reserve. This 
helps in deciding the initiating dose of gonadotropins for controlled ovarian hyper 
stimulation for optimal follicular response.
Keywords: ovary, controlled ovarian hyper stimulation, in vitro fertilization,  
ovarian reserve, ovulation
1. Introduction
Each natural ovulatory menstrual cycle has a 25% probability of spontaneous 
conception. Infertility is investigated when there is failure to conceive naturally 
following 1 year of unprotected intercourse in cases where the female is ≤35 years 
of age or following 6 months of unprotected intercourse for women >35 years of 
age. In 40% of the cases it can result due to female factor, in another 20% of cases 
it’s the male factor, which is the cause, and combined factors can cause infertility in 
about 20% of cases. The causative female factors can be further classified into tubal 
factors (40%), ovulatory factors (40%), uterine factors (10%) and cervical factors 
(10%). The commonest etiology of female infertility is ovulation dysfunctions and 
fallopian tube anatomical and physiological obstruction. The cornerstone first line 
examinations and investigations for the subfertile couple should detect of ovula-
tion and pituitary and ovarian secretion of hormones by hormonal assay (early 
follicular FSH and LH levels, mid-luteal progesterone) to assess the endogenous 
hypothalamo-pituitary-ovarian endometrial axis, and evaluation of tubal patency 
and function by diagnostic hysterolaparoscopy. GnRH hormone in hypothalamo-
pituitary portal circulation cannot be detected in peripheral blood samples.
2. Physiology of folliculogenesis
Ovaries are almond-shaped organs located in the pelvis on either side of the 
uterus. In addition to production of ova the ovaries are also a distinct endocrine 
organ producing hormones primarily estrogen and progesterone that are very 
important for normal reproductive function. The adult ovary can be divided into 
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3 main regions superficial to deep. These are the a. Cortex that consists of tunica 
albuginea ovarian follicles (primordial, primary, secondary, small medium, large 
Graafian follicles, and corpus luteum, atretic follicles. The B. medulla consists of 
blood vessels and nerves in connective tissue. The innermost hilum contains large 
spiral arteries and Leydig cells.
Normally the ovary produces a single dominant follicle in each menstrual cycle 
that undergoes maturation and results in ovulation (Figure 1). The granulosa cells 
of the growing follicles produce estradiol during the first half of the menstrual 
cycle or the follicular phase. The folliculogenesis begins with recruitment of a 
primordial follicle into a pool of growing follicles and it is a long process almost a 
year for a primordial follicle ultimately resulting in ovulation of the follicle or death 
by atresia. The process of folliculogenesis can be divided into 2 phases. First phase 
is “preantral” or “gonadotrophin independent” phase, where there is growth and 
differentiation of oocyte. The preantral phase mainly controlled by local factors 
growths factors by autocrine and paracrine processes. The second phase is the 
“gonadotrophin dependent” phase or the “antral phase” when there is a fast growth 
in the size of the follicle itself and it is under the control of gonadotrophin. The 
Antral phase is regulated by FSH and LH and also by paracrine growth factors that 
cause intracellular signaling and multiplication of cells.
The process of this folliculogenesis goes through multiple sub phases too. These 
include: 1. primordial follicle recruitment; 2. preantral follicle development; 3. 
Selection and growth of antral follicle; and 4. follicle atresia. The primordial follicle 
is the reproductive unit of ovary. It gives rise to dominant follicle. In human female 
fetus, primordial follicles are formed 6 and 9 months of gestation and many of 
the primordial follicles undergo apoptosis. The number of primordial follicles 
decreases progressively due to recruitment and apoptosis and very few of them are 
present after menopause. Primordial follicle recruitment is completely dependent 
on paracrine mechanism largely controlled by growth factors especially TGF-beta 
superfamily.
A primary follicle is in the next sequence that has the presence of one or more 
cuboidal granulosa cells arranged in a single layer around the oocyte. The most 
important event at this stage is the FSH receptor expression and oocyte growth and 
Figure 1. 
Folliculogenesis, ovulation and corpus luteal formation.
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maturation. Granulosa cells express receptors for FSH at this stage and the stimulus 
for this is FSH itself. Further development of primary follicle into preantral follicle 
is FSH dependent. The development of primary follicle is associated with striking 
change in oocyte too. Even there is a development of intimate connections between 
oocyte and granulose cells through the transzonal oocyte processes and gap junc-
tions (cumulus oophorus complex). FSH is an important factor in supporting 
follicle growth after antrum formation and in also preventing apoptosis thus it is a 
survival factor for antral follicles. Thus FSH plays a very important role in selection 
and dominant follicle development. The proliferation of granulosa cells is a very 
important feature for development of dominant follicles. FSH is the most important 
factor for granulosa cell proliferation.
As the granulosa cells proliferate and a dominant follicle develops it acquires the 
capacity to produce estradiol. FSH mediates the granulosa cells to acquire the above 
potential. The progressive increase in estradiol production by the dominant follicle 
from Day 7-Day 12 of menstrual cycle is only possible due to increased levels in 
P450AROM gene expression by FSH in granulosa cells.
The physiologic mechanism by which dominant follicle produces estradiol is 
the two cells two-gonadotrophin concept. When FSH recruits follicles to preovula-
tory development, their granulosa cells develop LH receptors, start undertaking 
aromatization and also inhibin production. Inhibin has the capability to increase 
LH stimulated thecal androgen production. LH receptors are present on theca cells 
throughout the menstrual cycle. LH acts on theca cells to produce primarily andro-
stenedione and to a lesser extent testosterone. Theca cell synthesized androstene-
dione is transported by paracrine circulation into the granulosa cells. In granulosa 
cells androstenedione and testosterone are aromatized to estrone and finally into 
estradiol by 17-β-hydroxysteroid dehydrogenase type I. This is known as the two-
cell, i.e., theca cell and follicular cell, two-gonadotropin, i.e., FSH and LH and two 
hormone, i.e., estradiol and progesterone theory of regulation of estrogen synthesis 
in the human ovary as shown in Figure 2. Granulosa cell derived inhibin takes 
part in a paracrine mechanism communicating with theca cells and thus amplify-
ing androgen synthesis. This theca cell derived androgen is converted to estradiol 
in granulosa cells of preovulatory follicles. Inhibin B has an early follicular phase 
elevation and lower values after ovulation. Thus it suggests Inhibin B is a granulosa 
cell product and can be a marker for follicular function, oocyte number and thus 
plays a role in follicular development in early part of the cycle.
2.1 Follicular phase
The follicular phase starts from the first day of menstrual cycle D1 until ovula-
tion. Basal body temperature chart normally shows lower values during this phase. 
Development growth trajectories of the ovarian follicles characterize this first 
phase of the cycle. Folliculogenesis starts during the last few days of the preceding 
menstrual cycle and continues till the release of the mature follicle at the time of 
ovulation. The primary development of the follicle to the preantral follicle is not 
gonadotropin dependent, and further follicular growth beyond this point requires 
gonadotropin action.
The secretion of gonadotropins from anterior pituitary is regulated by gonado-
tropin releasing hormone (GnRH), steroid hormones, and various peptides released 
by the dominant follicle. The growth of follicular size and number of granulosa cells 
in each follicle leads to an increase in estradiol serum concentrations in the early 
follicular phase. FSH receptors exist only on the granulosa cell membrane. There is 
increase in the number of FSH receptors with the gradual rise in serum FSH levels 
during the late follicular phase. The rise in serum FSH along with the rise in FSH 
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receptors leads to an increase in estradiol secretion by granulosa cells. It has to be 
noted at this point clearly that the increase in FSH receptor numbers is due to an 
increase in the population of granulosa cells and not an increase in the concentra-
tion of FSH receptors per granulosa cell. FSH has a positive stimulating effect for 
the formation of LH receptors on granulosa cells thus allowing the production of 
small quantities of progesterone and 17-hydroxyprogesterone (17-OHP) that exert a 
positive feedback on the estrogen-primed pituitary to augment luteinizing hormone 
(LH) release. Without LH, the increased progesterone synthesis from granulosa 
cells under the influence of FSH advances the endometrium and the resulting 
asynchronous development reduces the chances of embryo implantation (Figure 2). 
This phenomenon is also called as ENLOP or Elevated Non Luteinised Origin of 
Progesterone leading to displaced window of implantation. The addition of LH in 
follicular phase reduces premature progesterone increase and improves the likeli-
hood of implantation and clinical pregnancy.
FSH is elevated during the early follicular phase, declines as estradiol secretion 
increases from the granulosa cells, has a second rise before ovulation and then 
begins to decline until ovulation. FSH also stimulates several steroidogenic enzymes 
including aromatase, and 3β-hydroxysteroid dehydrogenase (3β-HSD). The second-
ary rise of FSH is important for inducing LH receptors on theca cells and granulosa 
cells and thereby preparing for the action of LH surge.
2.2 Luteal phase
The positive feedback from the rising estrogen levels during the follicular phase 
results in gradual increase in LH level by mid follicular phase that is low to start with 
during the early follicular phase. Estradiol levels must be greater than 200 pg/mL for 
approximately 50 hours in duration for the positive feedback effect of LH release to 
occur. During the early follicular phase, LH secretion occurs at a pulse frequency of 
Figure 2. 
Theca and granulosa cells (two cells) respond to luteinizing hormone and follicle stimulating hormone (two 
gonadotropins) to produce 17-OH progesterone and estradiol (two hormones).
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60 to 90 minutes with relatively constant pulse amplitude. During the late follicular 
phase prior to ovulation, the pulse frequency and may be amplitude of LH secretion 
increases. LH pulse amplitude increase results in ovulation [1, 2]. After ovulation 
corpus luteum is formed and theca cells continue to secrete progesterone.
The reduction of steroid production by the corpus luteum and the sudden fall of 
inhibin A allow the follicle stimulating hormone (FSH) to increase during the last 
few days of the menstrual cycle. In the late luteal phase, as corpus luteum lso degen-
erates there is no the estrogen and progesterone secretion from the ovary resulting 
in FSH rise because of increased GnRH pulsatile secretion. This elevation in FSH 
is very crucial for the recruitment of a cohort of ovarian follicles in each ovary out 
of that one follicle will be destined to ovulate during the next menstrual cycle. As 
menstruation starts the FSH levels begin to decline due to the negative feedback of 
estrogen and the negative effects of inhibin B produced by the developing follicle 
[1, 2]. The cyclical hormone changes are depicted in Figure 3.
3. Ovarian reserve
Ovarian reserve plays an important role in achieving pregnancy following any 
treatment in infertile and sub fertile women. The main function of the ovary in a 
woman is the production of a mature and viable oocyte that is capable of fertiliza-
tion and subsequently leads to an embryo development and implantation. At birth, 
each ovary has a fixed number of oocytes available for folliculogenesis during the 
later life. This fixed number of available oocytes is termed as “the ovarian reserve” 
of the woman. Delayed childbearing, voluntary or involuntary, is a common 
feature in couples visiting fertility clinics nowadays as they are career oriented and 
mostly working. The estimation of ovarian reserve is routinely performed prior to 
interventions through various ovarian reserve tests (ORTs) in an effort to predict 
the response and outcome in couples in vitro fertilization techniques and to even 
counsel them. The ovarian reserve estimation has to be routinely performed prior 
Figure 3. 
The cyclical harmonious balance of gonadotropin secretion from pituitary and estrogen and progesterone 
secretion from ovary results in LH surge resulting in final maturation of oocyte and ovulation.
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to any interventions for infertility through various ovarian reserve tests (ORTs) in 
an effort to predict the response and outcome in couples seeking help for infertil-
ity treatment such. The widely used tests are basal follicle stimulating hormone, 
Anti-Mullerian Hormone (AMH) and Antral Follicle Count (AFC). Ovarian reserve 
reduction is a physiological phenomenon characterized by declining follicular pool 
and oocyte quality. The reduction of ovarian reserve starts at about 30 years in 
south Asian population and at 35 years in Caucasians [3].This rate of age-related 
reduction of follicle count in the human ovary is more than doubles when numbers 
fall below a critical figure of 25,000 at ~37.5 years of age [4].
3.1 Ovarian reserve testing
Ovarian reserve tests (ORT) serve as an indirect measures of a woman’s remain-
ing follicular pool when she presents herself for infertility treatment. ORT should 
be easy to perform, should be sensitive, specific, valid, and help to individualize 
the starting dose of gonadotropins for multifollicular development. The ovarian 
reserve testing helps to differentiate normoresponders, hyporesponders, and hyper-
responders. Ovarian reserve is deciphered through a number of markers. These 
markers also help to prognosticate poor responders. Ovarian reserve is predicted 
clinically using a combination of clinical, biochemical and biophysical tests.
The tests are being used all over the world but the sensitivity and specificity of 
these test to detect the oocyte number, quality, and fecundity has to be still ascer-
tained with further research [5]. More recently, their value in predicting hyper-
response and hypo response and thus using safe stimulation regimes to prevent 
OHSS is also explored [2]. The interpretation of the results of the ovarian reserve 
test is complicated by the lack of uniform definitions for hypo or hyper-responders 
and uniform threshold values to identify abnormal results. Several static and 
dynamic ovarian functional markers like biological (age), biochemical, biophysical, 
and histological tests have been used to identify ovarian reserve [1, 2].
In most cases of decreased ovarian reserve, the cause remains undetected. In 
specific cases like exposure to chemotherapy, pelvic irradiation, and genetic abnor-
malities there is a premature decrease in ovarian pool of oocytes. Cigarette smoking 
has been associated with a decrease in ovarian reserve. With diminished ovarian 
reserve a reproductive age woman has regular periods with normal or shortened 
duration of menstrual cycles but there is a decrease in response to ovarian stimula-
tion and fecundity. Thus women of same age can differ in their response to ovarian 
stimulation and thus the fecundity can vary.
3.1.1 Age
It is long established that ovarian reserve reduces progressively with age. This is 
due to a combination of two factors the body ‘spending’ the eggs through routine 
ovulation and the ovaries aging and preparing for menopause. Individual varia-
tion of the ovarian reserve can be explained by the two instances given as- a young 
woman with certain reproductive health problems may start out with smaller than 
the normal reserve of healthy eggs, and some women’s reserves decrease more 
quickly than others with age. Fecundity in both natural and stimulated ovarian 
cycles declines with maternal age, beginning in the late 20s and becoming more 
abrupt in the late 30s. The fall in ovarian reserve with age in is a universal phenom-
enon in all ethinic groups. The initiation and rate of this decline varies considerably 
with ethinicity. Calender Age per se cannot determine ovarian responses. Ovarian 
reserve can also be traced indirectly by other biochemical and biophysical markers 
of ovarian function [6–11].
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3.1.2 Basal follicle stimulating hormone
One of the most classically used biochemical levels to measure ovarian reserve 
is the Basal follicle stimulating hormone (FSH) levels measured on day 3 of the 
menstrual cycle. An increase in FSH levels occurs due to follicle depletion as the 
age of the woman progresses [9, 10]. The measurement of FSH is easy, and inex-
pensive reproducible and its specific. FSH levels are known to have diurnal, intra- 
and intercycle variations that have to be kept in mind. There is definite precise 
parameter value to detect a woman with poor ovarian reserve. A vague demarking 
values more than 25 IU/L was used arbitrarily in some studies to detect high basal 
FSH. Several subsequent reviews did not identify values to satisfy the specificity 
and sensitivity for basal FSH as a test for poor ovarian response to stimulation or 
prediction of non-pregnancy. In women with regular menstrual cycles, FSH can 
predict a poor response adequately only at very high levels, and hence will be help-
ful only to a small number of women as a screening test for ovarian reserve testing 
and further counseling. It is thus clear that the ovarian aging begins several years 
prior to any elevation in FSH levels is noted and thus a normal test cannot rule out 
a poor ovarian response in some women. When FSH level is combined with other 
markers it can be used to counsel couples and planning treatment option regarding 
a poor response but it should not be used to exclude regularly cycling women from 
ART. The specificity of basal FSH testing in a general sub-fertile population or 
elevated levels in young, regularly cycling women is thus unclear and needs further 
studies [11–13]. Additionally the reliability of FSH is challengeable because of its 
pulsatile and circadian release and its isoforms. There are no cut off values available 
to predict poor responders.
3.1.3 Anti-Mullerian hormone
Anti-Mullerian hormone (AMH) is a dimeric glycoprotein exclusively produced 
by granulosa cells of preantral (primary and secondary) and very small and small 
antral follicles (2–6 mm) in the ovary. The serum levels of AMH reflect the number 
of follicles that have made the transition from primordial pool into the growing 
pool but still it is not under gonadotrophin control. The secretion of AMH starts 
once there is a follicular transition from the primordial to the primary stage, and it 
continues until the follicles reach till the follicles attain antral stages of diameters 
2–6 mm. The number of the small Antral Follicles indirectly reflects size of the 
primordial follicle pool. With the decrease in the number of the antral follicles 
with age, AMH production seems to reduce and become undetectable at and after 
menopause. The physiological function of AMH is to modulate primordial follicle 
recruitment. It inhibits the action of FSH on follicular growth and selection. AMH 
is considered to be reflective of FSH independent follicular growth, so it is a direct 
measure of ovarian reserve. AMH reflects qualitative and quantitative assessment 
of ovarian reserve. AMH levels also strongly correlate with basal antral follicle 
count (AFC) measured by transvaginal ultrasonography. Serum AMH levels corre-
late inversely with age from 25 years onwards and reaches undetectable levels after 
menopause, thus AMH levels is an important ovarian reserve marker. Serum AMH 
levels can be measured on any day of the cycle and does not exhibit inter-cycle vari-
ability unlike other biochemical markers. Threshold values of 0.2–1.26 ng/ml, have 
been used to identify poor responders with 80–87% sensitivity and 64–93% speci-
ficity. Thus by understanding of its clinical implications, AMH too has the potential 
to predict a hyper-response during treatment as well. The nomograms of the values 
of AMH can predict and identify the age-related physiological decline in the AMH 
levels and thus ovarian reserve, and abnormal deviation in the levels of AMH can be 
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used for counseling couples wishing to delay childbirth. Still the available evidence 
is not sufficient enough to suggest that serum AMH can be used as a single marker 
to predict pregnancy. Furthermore, studies of the levels of follicular fluid AMH has 
shown that oocytes obtained from follicles with higher levels of AMH have a better 
fertility potential compared to those with lower AMH levels [14–16]. Serum AMH 
estimations have also been useful to diagnose “Transitional Ovarian Failure” and 
“Insipient Ovarian Failure.”
Studies conducted longitudinally in fertile women have clearly shown a decline 
in serum AMH levels with progressing age. AMH is one of the earliest markers to 
show a decline progressively in young women with aging thus offering the prob-
ability of a screening test for women to counsel against delay in childbirth. Levels of 
0.5–1.26 ng/ml of AMH suggests impending menopause in next 3–5 years [17, 18]. 
AMH is also a most promising marker for predicting age of natural menopause too. 
The serum levels of AMH are not controlled by hypothalamus pituitary axis that 
makes it important marker in diagnosing conditions such as PCOS and premature 
ovarian failure.
3.1.4 Inhibin B
Inhibin B is a glycoprotein hormone produced by small ovarian follicular granu-
losa cells and thereby it is an indirect indicator of the follicular pool. Inhibin B is not 
a reliable parameter for measuring ovarian reserve though serum levels <45 pg/ml 
have been associated with poor response to controlled ovarian stimulation since it 
is not a reliable predictor of pregnancy. Inhibin B levels are lower in poor respond-
ers than in women with normal ovarian reserve. Inhibin B levels if exaggerated in 
stimulated cycle is an indicator of hyper response thus it can be used to monitor the 
response to exogenous FSH. Use of Inhibin B as a sole predictor of ovarian response 
is not recommended [19].
3.1.5 Basal estradiol
Estradiol is a steroid hormone secreted by the granulosa cells of the growing 
ovarian follicles. Day 2 or Day 3 basal estradiol is commonly assessed for observ-
ing the early oocyte development. Estradiol also exerts a negative feedback on the 
secretion of FSH from the pituitary thus high basal estradiol can reduce the FSH 
levels. Thus it is a helpful parameter in combination with FSH to establish the 
baseline ovarian reserve. Elevated basal estradiol has been associated with a poor 
response to ovarian stimulation. An early rise in serum estradiol is a characteristic 
sign of reproductive aging and can lower the elevated basal FSH into normal range 
thus resulting in misinterpretation of the test.
4. Clomiphene citrate challenge test
This is a dynamic test of ovarian function. This basically involves the Day 3 test-
ing of basal FSH levels and serum estradiol. Administering 100 mg of Clomiphene 
citrate tablets per day for 5 days from Day 5 to Day 9 of the cycle follows this. The 
FSH level is measured on Day 10 of the cycle. In cases of low reserve FSH is elevated 
on Day 10. FSH is the primary stimulus for final follicular maturation. It is under 
negative feedback from estradiol and inhibin B. Basal FSH levels are elevated it 
indicates a diminished follicular pool. Clomiphene citrate challenge test is a good 
predictor of ovarian reserve but not an absolute indicator of ovarian hypofunction. 
Thus the clinical value of CCCT is not clearly better than basal FSH and AFC in 
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combination. The Day 3 or Day10 FSH levels more than 10 mIU/ml is considered 
abnormal by most studies. Though there are different opinions still CCCT remains 
a gold standard in testing ovarian reserve. The justification of this test is that as the 
ovarian follicle develops in patients with normal ovarian function and will produce 
levels of inhibin and estradiol sufficient enough to suppress FSH production by 
Day 10 of the cycle concerned [20].Other dynamic tests used are GAST (GnRH 
Analogue Stimulation Test) and EFFORT (Exogenous FSH Ovarian Reserve Test).
5. Ultrasound parameters
5.1 Antral follicle count
After menarche, gradually a regular bi-fortnight ovulation is established. The 
immature oocyte covered with granulosa and theca cells rests in a small fluid filled 
cavity called as the antral follicle. These small fluid filled cavities are visualized 
sonologically in early follicular phase. These reflect follicles that were selected 
from the primordial follicle in this wave (wave theory of folliculogenensis) and so 
the antral follicle counts may vary in various mentstral cycles. There is no clear-
cut consensus on the criteria to identify antral follicles. Various litreture reviews 
suggest that the follicles with a diameter of 2 to 10 mm can be considered as AFa 
[5, 21]. Thus, the antral follicle count (AFC) is the number of follicles with cavity 
less than 10 mm in diameter with Transvaginal Ultrasound (TVUS) imaging in the 
early follicular phase of the cycle (Figure 4a–c). Antral follicle count is a quantita-
tive aspect of ovarian aging. As a direct marker of the cohort of growing follicles 
Figure 4. 
(a) Ovarian antral follicular count in hypo responders; (b) ovarian antral follicular count in normal 
responders; and (c) ovarian antral follicular count in hyper responders.
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in the early menstrual cycle, the AFC is believed to correlate strongly with the 
number of primordial follicles present in the ovary and, thus, the ovarian reserve. 
Antral Follicles are routinely measured by 2 D transvaginal ultrasonography in the 
early follicular phase, by taking the mean of two perpendicular measurements. 
Inversion made is useful for counting multiple follicles. The numbers of follicles 
in both ovaries are added for the total Antral Follicle count. (AFC). AFC has been 
predominantly used as a marker of ovarian reserve over a period of time. A count of 
8–10 is taken as a normal response of ovaries. Different diameters are used to define 
antral follicles of varying sizes as those measuring 2–6 and 7–10 mm. There is no 
clear consensus regarding the size of antral follicles, which truly represent ovarian 
reserve. The number of small antral follicles (2–6 mm) is significantly related to age 
and also to all endocrine ORTs tested, suggesting the number of small antral fol-
licles represents the functional ovarian reserve. It is seen that the number of antral 
follicles of 2–6 mm in size decreases with age and correlates with other markers such 
as serum basal FSH and CCCT whereas follicles of size 7–10 mm remains constant 
and thus, the former appears to be a more reliable marker of ovarian reserve. 
Measurements taken repeatedly of the antral follicles have shown that there is only 
a limited intercycle variability. 3D ultrasound imaging also does not carry any better 
advantage in comparison to 2D ultrasound for the detection of functional ovarian 
reserve [22–25]. Meta-analyses showed that women with AFC less than four were 
8.7 times more likely not to get pregnant after IVF (two studies; 95% CI,) than 
women with AFC four or more. The sensitivity and specificity of AFC to predict 
cycle cancelation was 66.7 and 94.7%, respectively [21].
5.2 Ovarian volume
The volume of the ovaries is calculated by imaging and callipering the ovary 
in three perpendicular planes with using the formula of ellipsoid volume as 
(L1 × L2 × L3 × π/6). An alternative automatic method is calculation of Ovarian 
volume through “virtual organ computer-aided analysis” or VOCAL. The predictive 
performance of ovarian volume toward poor response is clearly inferior compared 
with that of AFC. Therefore, the AFC may be considered the test of first choice 
when estimating quantitative ovarian reserve before IVF. Total Basal Ovarian 
Volume (BOV) is obtained by adding the volumes of both. The ovarian volume is 
constant till the perimenopausal period and the measurement does not increase the 
Figure 5. 
Doppler ovarian stromal vascularity measurements with 2D doppler calculation of pulsatility index and 
resistivity index.
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positive predictive value of AFC. Furthermore, the decrease in the Basal Ovarian 
Volume is a very late phenomenon women >40 years [25, 26]. Ovarian volume 
measurement, at a cut off value of 3 cm3, showed specificity for prediction of cycle 
cancelation and non-pregnancy of 92% (three studies, 95% CI, 89–94) and 93% 
(three studies, 95% CI), respectively [21].
5.3 Ovarian stromal vascularity
The observation of the ovarian stromal Doppler flow during ovarian stimulation 
has been studied in IVF cycles. Poor ovarian stromal vascularization impairs the access 
of gonadotropins to the ovarian follicles. Power Doppler US in combination with 3D 
VOCAL is an appropriate approach for correlating the ovarian vascular network with 
the ovarian response to ART. The gradual increase in the Doppler flow noted during 
stimulation may provide additional information to AFC (Figure 5) [27–36].
6. Conclusion
Ovarian pathophysiology is complex. Ovarian folliculogenesis follicular rupture 
and luteal transition should be studied elaborately. Endometrial evaluation should 
be also done in a nonstimulated cycle. Serum hormone values should be measured 
in normal non-induced menstrual cycle to study the ovarian reserve and detect any 
undiagnosed synchronizing defects in embryo invasion and endometrial implanta-
tion window. Sonoendocrinology is a new imaging science deciphers the hormonal 
action on target organs. Antral follicle count, at a cut off value of less than four, 
had high specificity for the prediction of cycle cancelation in assisted reproduction. 
Ovarian volume, at a cut-off value 3 mL3, had high specificity for the prediction of 
non-pregnancy and cycle cancelation in assisted reproduction. Doppler studies of 
ovarian stromal blood flow are promising, but more research is needed. AFC and 
ovarian volume provide direct measurements of ovarian response, while AMH, 
Inhibin B and estradiol are released from the growing follicles and so they reflect 
the follicular cohort that has been selected from the follicular pool.
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